

20 Feb 2022 | News

Quick Listen: Scrip's Five Must-Know Things

by **Ian Haydock**

In this week's podcast edition of Five Must-Know Things: Lynparza poised for expansion in prostate cancer; zuranolone faces challenges in depression; Novartis transfers products and cuts jobs in India; US call to build Alzheimer's infrastructure; and Indian legal row over COVID spray product.

Join us for an audio catch-up on the major events in the biopharma industry over the past business week, as reported by *Scrip's* global team, in this podcast version of Five Must-Know Things.

This episode covers insights for the business week ended 18 February 2022, including: Lynparza poised for expansion in prostate cancer; zuranolone faces challenges in depression; [Novartis AG](#) transfers products and cuts jobs in India; US call to build Alzheimer's infrastructure; and Indian legal row over COVID spray product.

This and all our other podcasts are available on the Informa Pharma Intelligence channel on [Apple Podcasts](#), [Google Podcasts](#), [SoundCloud](#), [TuneIn](#) and [Spotify Podcasts](#), and via smart speakers if one of these platforms has been set up as your default podcast provider.

Stories mentioned in this episode:

(Also see "[Lynparza On Track For Broad Frontline Use In Prostate Cancer](#)" - Scrip, 15 Feb, 2022.)

(Also see "[Sage/Biogen Depression Data Likely To Prolong Commercial Debate](#)" - Scrip, 16 Feb, 2022.)

(Also see "[Novartis-Dr Reddy's Sales Pact, Job Cuts: Are Foreign Firms Altering India Push?](#)" - Scrip, 14 Feb, 2022.)

(Also see "[*Work Now To Build The Alzheimer's Commercial Landscape, McClellan Advises*](#)" - Scrip, 15 Feb, 2022.)

(Also see "[*SaNOtize, Lupin In Legal Row Concerning COVID-19 Nasal Spray*](#)" - Scrip, 14 Feb, 2022.)

[Click here to explore this interactive content online](#) ✨